RWE 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
Australia has several real-world evidence (RWE) initiatives to support healthcare and drug development. The Therapeutic Goods Administration (TGA) has established a framework for the use of real-world data (RWD) and RWE in regulatory decision-making, which includes the use of data from electronic health records and disease registries [1]. Following the 2021 Review into the usage of RWE and patient-reported outcomes (PROs) in the regulation of medicines and medical devices, the TGA has been working on incorporating RWE and PROs into its regulatory processes [2][3][4].
Additionally, the Medicines Intelligence Centre of Research Excellence (MI-CRE) was established to generate timely research supporting the evidentiary needs of Australian medicines regulators and payers by accelerating the development and translation of RWE on medicines use and outcomes [4]. MI-CRE aims to equip the next generation of medicines researchers in Australia with the skills to co-create evidence with end-users [5].
Despite these initiatives, there are still challenges and gaps in Australia’s RWE landscape. A review on generating RWE on the quality use, benefits, and safety of medicines in Australia highlights the need for a roadmap to bolster Australia’s capacity to accelerate evidence development about the effectiveness, safety, and quality use of medicines in routine clinical care [6]. Robust RWE generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable healthcare and improve the health and well-being of all Australians [6].
References:
[1] https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/
[2] https://www.tga.gov.au/real-world-evidence-rwe-and-patient-reported-outcomes-pros
[4] https://www.sciencedirect.com/science/article/pii/S0149291822000170
[5] https://ijpds.org/article/view/1726
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707536/
Share this story...
Real World Evidence (RWE) 201…THE END – A Landscape Analysis of Regional RWE Frameworks – The European Health Data Space and DARWIN-EU
RWE 201 - THE END - A Landscape Analysis of Regional RWE Frameworks - The European Health Data Space and DARWIN-EU In our real world evidence (RWE) 201 series [...]
Real World Evidence (RWE) – Event Horizon
RWE 201 - RWE Event Horizon The term "event horizon" in the context of pharmaceuticals, particularly when discussing the shift towards real-world evidence (RWE) in regulatory submissions, is metaphorically [...]
Real World Evidence (RWE) 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
RWE 201 - Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development Australia has several real-world evidence (RWE) initiatives to support healthcare [...]
Real World Evidence (RWE) 201 – South Korea’s Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development
RWE 201 - South Korea's Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development South Korea has several initiatives to support healthcare and drug development using [...]
Real World Evidence (RWE) 201 – Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making
RWE 201 - Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making Taiwan has several real-world evidence (RWE) initiatives to support healthcare and drug development. Over the past [...]
Real World Evidence (RWE) 201 – Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development
RWE 201 - Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development Japan has several initiatives to support healthcare and drug development using real-world evidence (RWE). [...]
